首页 > 最新文献

World Journal of Gastrointestinal Pathophysiology最新文献

英文 中文
Gut microbiome: Linking together obesity, bariatric surgery and associated clinical outcomes under a single focus. 肠道微生物组:将肥胖、减肥手术和相关临床结果联系在一起。
Pub Date : 2022-05-22 DOI: 10.4291/wjgp.v13.i3.59
Konstantinos Georgiou, Nikolay A Belev, Tilemachos Koutouratsas, Hector Katifelis, Maria Gazouli

Obesity is increasingly prevalent in the post-industrial era, with increased mortality rates. The gut microbiota has a central role in immunological, nutritional and metabolism mediated functions, and due to its multiplexity, it is considered an independent organ. Modern high-throughput sequencing techniques have allowed phylogenetic exploration and quantitative analyses of gut microbiome and improved our current understanding of the gut microbiota in health and disease. Its role in obesity and its changes following bariatric surgery have been highlighted in several studies. According to current literature, obesity is linked to a particular microbiota profile that grants the host an augmented potential for calorie release, while limited diversity of gut microbiome has also been observed. Moreover, bariatric surgery procedures represent effective interventions for sustained weight loss and restore a healthier microbiota, contributing to the observed fat mass reduction and lean mass increase. However, newer evidence has shown that gut microbiota is only partially recovered following bariatric surgery. Moreover, several targets including FGF15/19 (a gut-derived peptide), could be responsible for the favorable metabolic changes of bariatric surgery. More randomized controlled trials and larger prospective studies that include well-defined cohorts are required to better identify associations between gut microbiota, obesity, and bariatric surgery.

肥胖在后工业时代越来越普遍,死亡率也在上升。肠道微生物群在免疫、营养和代谢介导的功能中起着核心作用,由于其多样性,它被认为是一个独立的器官。现代高通量测序技术已经允许肠道微生物群的系统发育探索和定量分析,并提高了我们目前对健康和疾病肠道微生物群的理解。它在肥胖中的作用及其在减肥手术后的变化已在几项研究中得到强调。根据目前的文献,肥胖与特定的微生物群有关,这些微生物群赋予宿主增加卡路里释放的潜力,同时也观察到肠道微生物群的多样性有限。此外,减肥手术是持续减肥和恢复更健康的微生物群的有效干预措施,有助于观察到的脂肪质量减少和瘦质量增加。然而,新的证据表明,在减肥手术后,肠道微生物群只是部分恢复。此外,包括FGF15/19(一种肠道衍生肽)在内的几个靶点可能是减肥手术中有利的代谢变化的原因。需要更多的随机对照试验和更大的前瞻性研究,包括明确的队列,以更好地确定肠道微生物群,肥胖和减肥手术之间的关系。
{"title":"Gut microbiome: Linking together obesity, bariatric surgery and associated clinical outcomes under a single focus.","authors":"Konstantinos Georgiou,&nbsp;Nikolay A Belev,&nbsp;Tilemachos Koutouratsas,&nbsp;Hector Katifelis,&nbsp;Maria Gazouli","doi":"10.4291/wjgp.v13.i3.59","DOIUrl":"https://doi.org/10.4291/wjgp.v13.i3.59","url":null,"abstract":"<p><p>Obesity is increasingly prevalent in the post-industrial era, with increased mortality rates. The gut microbiota has a central role in immunological, nutritional and metabolism mediated functions, and due to its multiplexity, it is considered an independent organ. Modern high-throughput sequencing techniques have allowed phylogenetic exploration and quantitative analyses of gut microbiome and improved our current understanding of the gut microbiota in health and disease. Its role in obesity and its changes following bariatric surgery have been highlighted in several studies. According to current literature, obesity is linked to a particular microbiota profile that grants the host an augmented potential for calorie release, while limited diversity of gut microbiome has also been observed. Moreover, bariatric surgery procedures represent effective interventions for sustained weight loss and restore a healthier microbiota, contributing to the observed fat mass reduction and lean mass increase. However, newer evidence has shown that gut microbiota is only partially recovered following bariatric surgery. Moreover, several targets including FGF15/19 (a gut-derived peptide), could be responsible for the favorable metabolic changes of bariatric surgery. More randomized controlled trials and larger prospective studies that include well-defined cohorts are required to better identify associations between gut microbiota, obesity, and bariatric surgery.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"13 3","pages":"59-72"},"PeriodicalIF":0.0,"publicationDate":"2022-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/07/WJGP-13-59.PMC9157685.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40013024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Increasing thirty-day readmissions of Crohn's disease and ulcerative colitis in the United States: A national dilemma. 美国克罗恩病和溃疡性结肠炎的三十天再入院率不断上升:全国性难题。
Pub Date : 2022-05-22 DOI: 10.4291/wjgp.v13.i3.85
Dushyant Singh Dahiya, Abhilash Perisetti, Asim Kichloo, Amandeep Singh, Hemant Goyal, Laura Rotundo, Madhu Vennikandam, Hafeez Shaka, Gurdeep Singh, Jagmeet Singh, Sailaja Pisipati, Mohammad Al-Haddad, Madhusudhan R Sanaka, Sumant Inamdar

Background: The prevalence of Crohn's disease (CD) and ulcerative colitis (UC) is on the rise worldwide. This rising prevalence is concerning as patients with CD and UC may frequently relapse leading to recurrent hospitalizations and increased healthcare utilization.

Aim: To identify trends and adverse outcomes for 30 d readmissions for CD and UC.

Methods: This was a retrospective, interrupted trends study involving all adult (≥ 18 years) 30 d readmissions of CD and UC from the National Readmission Database (NRD) between 2008 and 2018. Patients < 18 years, elective, and traumatic hospitalizations were excluded from this study. We identified hospitalization characteristics and readmission rates for each calendar year. Trends of inpatient mortality, mean length of hospital stay (LOS) and mean total hospital cost (THC) were calculated using a multivariate logistic trend analysis adjusting for age, gender, insurance status, comorbidity burden and hospital factors. Furthermore, trends between CD and UC readmissions were compared using regression of the interaction coefficient after adjusting for age and gender to determine relative trends between the two populations. Stata® Version 16 software (StataCorp, TX, United States) was used for statistical analysis and P value ≤ 0.05 were considered statistically significant.

Results: Total number of 30 d readmissions increased from 6202 in 2010 to 7672 in 2018 for CD and from 3272 in 2010 to 4234 in 2018 for UC. We noted increasing trends for 30-day all-cause readmission rate of CD from 14.9% in 2010 to 17.6% in 2018 (P-trend < 0.001), CD specific readmission rate from 7.1% in 2010 to 8.2% in 2018 (P-trend < 0.001), 30-day all-cause readmission rate of UC from 14.1% in 2010 to 15.7% in 2018 (P-trend = 0.003), and UC specific readmission rate from 5.2% in 2010 to 5.6% in 2018 (P-trend = 0.029). There was no change in the risk adjusted trends of inpatient mortality and mean LOS for CD and UC readmissions. However, we found an increasing trend of mean THC for UC readmissions. After comparison, there was no statistical difference in the trends for 30 d all-cause readmission rate, inpatient mortality, and mean LOS between CD and UC readmissions.

Conclusion: There was an increase in total number of 30 d readmissions for CD and UC with a trend towards increasing 30 d all-cause readmission rates.

背景:克罗恩病(CD)和溃疡性结肠炎(UC)的发病率在全球呈上升趋势。这种发病率的上升令人担忧,因为克罗恩病和溃疡性结肠炎患者可能会经常复发,导致反复住院和医疗费用的增加。目的:确定克罗恩病和溃疡性结肠炎患者 30 d 再入院的趋势和不良后果:这是一项回顾性、间断趋势研究,涉及 2008 年至 2018 年间全国再入院数据库(NRD)中所有成人(≥ 18 岁)CD 和 UC 30 d 再入院患者。本研究排除了年龄小于 18 岁的患者、择期住院患者和创伤性住院患者。我们确定了每个日历年的住院特征和再入院率。使用多变量逻辑趋势分析计算了住院患者死亡率、平均住院时间(LOS)和平均住院总费用(THC)的趋势,并对年龄、性别、保险状况、合并症负担和医院因素进行了调整。此外,在对年龄和性别进行调整后,使用交互系数回归法比较了 CD 和 UC 再入院的趋势,以确定两种人群之间的相对趋势。统计分析采用Stata® 16版软件(StataCorp,德克萨斯州,美国),P值≤0.05为有统计学意义:CD的30天再入院总数从2010年的6202例增加到2018年的7672例,UC的30天再入院总数从2010年的3272例增加到2018年的4234例。我们注意到,CD 的 30 天全因再入院率从 2010 年的 14.9% 上升至 2018 年的 17.6%(P-趋势 < 0.001),CD 特定再入院率从 2010 年的 7.1% 上升至 2018 年的 8.2%(P-趋势 < 0.001),UC 的 30 天全因再入院率从 2010 年的 14.1% 上升至 2018 年的 15.7%(P-趋势 = 0.003),UC 特定再入院率从 2010 年的 5.2% 上升至 2018 年的 5.6%(P-趋势 = 0.029)。CD和UC再入院的住院患者死亡率和平均住院日的风险调整趋势没有变化。然而,我们发现 UC 再入院的平均 THC 呈上升趋势。经过比较,CD 和 UC 再入院患者的 30 d 全因再入院率、住院患者死亡率和平均住院日趋势没有统计学差异:CD和UC的30 d再入院总数有所增加,30 d全因再入院率也呈上升趋势。
{"title":"Increasing thirty-day readmissions of Crohn's disease and ulcerative colitis in the United States: A national dilemma.","authors":"Dushyant Singh Dahiya, Abhilash Perisetti, Asim Kichloo, Amandeep Singh, Hemant Goyal, Laura Rotundo, Madhu Vennikandam, Hafeez Shaka, Gurdeep Singh, Jagmeet Singh, Sailaja Pisipati, Mohammad Al-Haddad, Madhusudhan R Sanaka, Sumant Inamdar","doi":"10.4291/wjgp.v13.i3.85","DOIUrl":"10.4291/wjgp.v13.i3.85","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of Crohn's disease (CD) and ulcerative colitis (UC) is on the rise worldwide. This rising prevalence is concerning as patients with CD and UC may frequently relapse leading to recurrent hospitalizations and increased healthcare utilization.</p><p><strong>Aim: </strong>To identify trends and adverse outcomes for 30 d readmissions for CD and UC.</p><p><strong>Methods: </strong>This was a retrospective, interrupted trends study involving all adult (≥ 18 years) 30 d readmissions of CD and UC from the National Readmission Database (NRD) between 2008 and 2018. Patients < 18 years, elective, and traumatic hospitalizations were excluded from this study. We identified hospitalization characteristics and readmission rates for each calendar year. Trends of inpatient mortality, mean length of hospital stay (LOS) and mean total hospital cost (THC) were calculated using a multivariate logistic trend analysis adjusting for age, gender, insurance status, comorbidity burden and hospital factors. Furthermore, trends between CD and UC readmissions were compared using regression of the interaction coefficient after adjusting for age and gender to determine relative trends between the two populations. Stata<sup>®</sup> Version 16 software (StataCorp, TX, United States) was used for statistical analysis and <i>P</i> value ≤ 0.05 were considered statistically significant.</p><p><strong>Results: </strong>Total number of 30 d readmissions increased from 6202 in 2010 to 7672 in 2018 for CD and from 3272 in 2010 to 4234 in 2018 for UC. We noted increasing trends for 30-day all-cause readmission rate of CD from 14.9% in 2010 to 17.6% in 2018 (<i>P</i>-trend < 0.001), CD specific readmission rate from 7.1% in 2010 to 8.2% in 2018 (<i>P</i>-trend < 0.001), 30-day all-cause readmission rate of UC from 14.1% in 2010 to 15.7% in 2018 (<i>P</i>-trend = 0.003), and UC specific readmission rate from 5.2% in 2010 to 5.6% in 2018 (<i>P</i>-trend = 0.029). There was no change in the risk adjusted trends of inpatient mortality and mean LOS for CD and UC readmissions. However, we found an increasing trend of mean THC for UC readmissions. After comparison, there was no statistical difference in the trends for 30 d all-cause readmission rate, inpatient mortality, and mean LOS between CD and UC readmissions.</p><p><strong>Conclusion: </strong>There was an increase in total number of 30 d readmissions for CD and UC with a trend towards increasing 30 d all-cause readmission rates.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"13 3","pages":"85-95"},"PeriodicalIF":0.0,"publicationDate":"2022-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/33/49/WJGP-13-85.PMC9157684.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40013022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities. 基于fibroscan的评分系统用于缩小非酒精性脂肪性肝病合并症的风险组
Pub Date : 2022-05-22 DOI: 10.4291/wjgp.v13.i3.96
Kouichi Miura, Hiroshi Maeda, Naoki Morimoto, Shunji Watanabe, Mamiko Tsukui, Yoshinari Takaoka, Hiroaki Nomoto, Rie Goka, Kazuhiko Kotani, Hironori Yamamoto

Background: Vibration-controlled transient elastography (VCTE) is proposed as a second step of examination to assess liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) after triaging by the fibrosis-4 (FIB-4) index. Recently, VCTE-based scoring systems, including FibroScan-AST (FAST), Agile 3+, and Agile 4, emerged to determine the status of NAFLD. However, the significance of these scoring systems remains unknown in narrowing the high-risk group of NAFLD patients with comorbidities, including hepatocellular carcinoma (HCC) and esophagogastric varices (EGV).

Aim: To clarify the significance of VCTE-based scoring systems to narrow the high-risk group of NAFLD patients with comorbidities.

Methods: We performed a cross-sectional study to investigate the usefulness of VCTE-based scoring systems and other fibrosis markers to narrow the high-risk group of patients with NAFLD. FIB-4 index was used for the first triage. Risk groups of FAST, Agile 3+, and Agile 4 were stratified according to the published data. Among the 191 patients with NAFLD, there were 26 (14%) and 25 patients (13%) with HCC and EGV, respectively.

Results: When 1.3 was used as a cutoff value, the FIB-4 index narrowed the risk group to 120 patients, in which all patients with HCC and/or EGV were included. High risk group of Agile 3+ could subsequently narrow the risk group. The prevalence of HCC and EGV at this step were 33% (26/80) and 31% (25/80), respectively. In further narrowing of EGV, Agile 4 aggregated the patients with EGV into 43 patients, of whom 23 (53%) had EGV. FAST failed to narrow the risk group of patients with comorbidities. When 2.6 was used as a cutoff value of the FIB-4 index, three patients with HCC and two patients with EGV were missed at the first triage.

Conclusion: Agile 3+ and Agile 4 are useful to narrow the NAFLD patient group, in which patients may have HCC and/or EGV.

背景:振动控制瞬时弹性成像(VCTE)被提议作为评估非酒精性脂肪性肝病(NAFLD)患者在纤维化-4 (FIB-4)指数分类后肝纤维化的第二步检查。最近,基于vcte的评分系统,包括纤维扫描- ast (FAST)、Agile 3+和Agile 4,出现用于确定NAFLD的状态。然而,这些评分系统在缩小NAFLD合并症高危人群(包括肝细胞癌(HCC)和食管胃静脉曲张(EGV))中的意义尚不清楚。目的:阐明基于vcte评分系统对缩小NAFLD合并症高危人群的意义。方法:我们进行了一项横断面研究,以调查基于vcte的评分系统和其他纤维化标志物对缩小NAFLD患者高危组的有用性。采用FIB-4指数进行首次分诊。根据已发表的数据对FAST、Agile 3+和Agile 4的风险组进行分层。191例NAFLD患者中,HCC和EGV患者分别为26例(14%)和25例(13%)。结果:当使用1.3作为临界值时,FIB-4指数将风险组缩小到120例,其中包括所有HCC和/或EGV患者。Agile 3+的高风险组随后会缩小风险组。此阶段HCC和EGV的患病率分别为33%(26/80)和31%(25/80)。为了进一步缩小EGV, Agile 4将EGV患者汇总为43例,其中23例(53%)为EGV。FAST未能缩小合并合并症患者的风险组。当FIB-4指数的临界值为2.6时,3例HCC患者和2例EGV患者在第一次分诊时被遗漏。结论:Agile 3+和Agile 4有助于缩小NAFLD患者组,其中可能有HCC和/或EGV。
{"title":"Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities.","authors":"Kouichi Miura,&nbsp;Hiroshi Maeda,&nbsp;Naoki Morimoto,&nbsp;Shunji Watanabe,&nbsp;Mamiko Tsukui,&nbsp;Yoshinari Takaoka,&nbsp;Hiroaki Nomoto,&nbsp;Rie Goka,&nbsp;Kazuhiko Kotani,&nbsp;Hironori Yamamoto","doi":"10.4291/wjgp.v13.i3.96","DOIUrl":"https://doi.org/10.4291/wjgp.v13.i3.96","url":null,"abstract":"<p><strong>Background: </strong>Vibration-controlled transient elastography (VCTE) is proposed as a second step of examination to assess liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) after triaging by the fibrosis-4 (FIB-4) index. Recently, VCTE-based scoring systems, including FibroScan-AST (FAST), Agile 3+, and Agile 4, emerged to determine the status of NAFLD. However, the significance of these scoring systems remains unknown in narrowing the high-risk group of NAFLD patients with comorbidities, including hepatocellular carcinoma (HCC) and esophagogastric varices (EGV).</p><p><strong>Aim: </strong>To clarify the significance of VCTE-based scoring systems to narrow the high-risk group of NAFLD patients with comorbidities.</p><p><strong>Methods: </strong>We performed a cross-sectional study to investigate the usefulness of VCTE-based scoring systems and other fibrosis markers to narrow the high-risk group of patients with NAFLD. FIB-4 index was used for the first triage. Risk groups of FAST, Agile 3+, and Agile 4 were stratified according to the published data. Among the 191 patients with NAFLD, there were 26 (14%) and 25 patients (13%) with HCC and EGV, respectively.</p><p><strong>Results: </strong>When 1.3 was used as a cutoff value, the FIB-4 index narrowed the risk group to 120 patients, in which all patients with HCC and/or EGV were included. High risk group of Agile 3+ could subsequently narrow the risk group. The prevalence of HCC and EGV at this step were 33% (26/80) and 31% (25/80), respectively. In further narrowing of EGV, Agile 4 aggregated the patients with EGV into 43 patients, of whom 23 (53%) had EGV. FAST failed to narrow the risk group of patients with comorbidities. When 2.6 was used as a cutoff value of the FIB-4 index, three patients with HCC and two patients with EGV were missed at the first triage.</p><p><strong>Conclusion: </strong>Agile 3+ and Agile 4 are useful to narrow the NAFLD patient group, in which patients may have HCC and/or EGV.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"13 3","pages":"96-106"},"PeriodicalIF":0.0,"publicationDate":"2022-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/af/b3/WJGP-13-96.PMC9157683.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40013026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises). 肝细胞癌的分子和遗传标记:从硅学分析到临床验证(目前的局限性和未来的前景)。
Pub Date : 2022-01-22 DOI: 10.4291/wjgp.v13.i1.1
Sarah El-Nakeep

Hepatocellular carcinoma (HCC) is the second cause of cancer-related mortality. The diagnosis of HCC depends mainly on -fetoprotein, which is limited in its diagnostic and screening capabilities. There is an urgent need for a biomarker that detects early HCC to give the patients a chance for curative treatment. New targets of therapy could enhance survival and create future alternative curative methods. In silico analysis provides both; discovery of biomarkers, and understanding of the molecular pathways, to pave the way for treatment development. This review discusses the role of in silico analysis in the discovery of biomarkers, molecular pathways, and the role the author has contributed to this area of research. It also discusses future aspirations and current limitations. A literature review was conducted on the topic using various databases (PubMed, Science Direct, and Wiley Online Library), searching in various reviews, and editorials on the topic, with overviewing the author's own published and unpublished work. This review discussed the steps of the validation process from in silico analysis to in vivo validation, to incorporation into clinical practice guidelines. In addition, reviewing the recent lines of research of bioinformatic studies related to HCC. In conclusion, the genetic, molecular and epigenetic markers discoveries are hot areas for HCC research. Bioinformatics will enhance our ability to accomplish this understanding in the near future. We face certain limitations that we need to overcome.

肝细胞癌(HCC)是导致癌症相关死亡的第二大原因。HCC 的诊断主要依赖于-甲胎蛋白,但其诊断和筛查能力有限。目前急需一种能检测早期 HCC 的生物标志物,以使患者有机会接受根治性治疗。新的治疗目标可以提高生存率,并创造未来的替代治疗方法。硅学分析既能发现生物标志物,又能了解分子通路,为开发治疗方法铺平道路。这篇综述讨论了硅学分析在发现生物标志物和分子途径方面的作用,以及作者在这一研究领域的贡献。它还讨论了未来的期望和目前的局限性。我们利用各种数据库(PubMed、Science Direct 和 Wiley Online Library)对该主题进行了文献综述,在各种评论和有关该主题的社论中进行了搜索,并概述了作者本人已发表和未发表的工作。这篇综述讨论了从硅学分析到体内验证再到纳入临床实践指南的验证过程的各个步骤。此外,还回顾了与 HCC 相关的生物信息学研究的最新进展。总之,基因、分子和表观遗传标记的发现是 HCC 研究的热点领域。在不久的将来,生物信息学将提高我们完成这一认识的能力。我们面临着一些需要克服的局限性。
{"title":"Molecular and genetic markers in hepatocellular carcinoma: <i>In silico</i> analysis to clinical validation (current limitations and future promises).","authors":"Sarah El-Nakeep","doi":"10.4291/wjgp.v13.i1.1","DOIUrl":"10.4291/wjgp.v13.i1.1","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the second cause of cancer-related mortality. The diagnosis of HCC depends mainly on -fetoprotein, which is limited in its diagnostic and screening capabilities. There is an urgent need for a biomarker that detects early HCC to give the patients a chance for curative treatment. New targets of therapy could enhance survival and create future alternative curative methods. <i>In silico</i> analysis provides both; discovery of biomarkers, and understanding of the molecular pathways, to pave the way for treatment development. This review discusses the role <i>of in silico</i> analysis in the discovery of biomarkers, molecular pathways, and the role the author has contributed to this area of research. It also discusses future aspirations and current limitations. A literature review was conducted on the topic using various databases (PubMed, Science Direct, and Wiley Online Library), searching in various reviews, and editorials on the topic, with overviewing the author's own published and unpublished work. This review discussed the steps of the validation process from <i>in silico</i> analysis to <i>in vivo</i> validation, to incorporation into clinical practice guidelines. In addition, reviewing the recent lines of research of bioinformatic studies related to HCC. In conclusion, the genetic, molecular and epigenetic markers discoveries are hot areas for HCC research. Bioinformatics will enhance our ability to accomplish this understanding in the near future. We face certain limitations that we need to overcome.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"13 1","pages":"1-14"},"PeriodicalIF":0.0,"publicationDate":"2022-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/fb/WJGP-13-1.PMC8788164.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39588560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current treatment strategies and future perspectives for gastrointestinal stromal tumors. 胃肠道间质瘤的当前治疗策略及未来展望。
Pub Date : 2022-01-22 DOI: 10.4291/wjgp.v13.i1.15
Yoichi Sugiyama, Masaru Sasaki, Mohei Kouyama, Tatsuya Tazaki, Shinya Takahashi, Atsushi Nakamitsu

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that originate from the gastrointestinal tract, mostly from the stomach. GISTs are derived from the myenteric interstitial cells of Cajal and are caused by several mutations in the c-kit and platelet-derived growth factor receptor genes. Clinically, GISTs are detected by endoscopic and imaging findings and are diagnosed by immunostaining. Surgery is the first line of treatment, and if the tumor is relatively small, minimally invasive surgery such as laparoscopy is performed. In recent years, neoadjuvant therapy has been administered to patients with GISTs that are suspected of having a large size or infiltration to other organs. Postoperative adjuvant imatinib is the standard therapy for high-risk GISTs. It is important to assess the risk of recurrence after GIST resection. However, the effect of tyrosine kinase inhibitor use will vary by the mutation of c-kit genes and the site of mutation. Furthermore, information regarding gene mutation is indispensable when considering the treatment policy for recurrent GISTs. This article reviews the clinicopathological characteristics of GISTs along with the minimally invasive and multidisciplinary treatment options available for these tumors. The future perspectives for diagnostic and treatment approaches for these tumors have also been discussed.

胃肠道间质瘤(gist)是一种起源于胃肠道的间质肿瘤,主要来自胃。gist来源于Cajal的肌间质细胞,由c-kit和血小板源性生长因子受体基因的几种突变引起。临床上,gist通过内窥镜和影像学检查发现,并通过免疫染色诊断。手术是治疗的第一线,如果肿瘤比较小,则进行腹腔镜等微创手术。近年来,新辅助治疗已被用于怀疑有较大体积或浸润到其他器官的胃肠道间质瘤患者。术后辅助伊马替尼是高危gist的标准治疗。评估GIST切除术后复发的风险是很重要的。然而,酪氨酸激酶抑制剂的使用效果会因c-kit基因的突变和突变部位而异。此外,在考虑复发性gist的治疗策略时,有关基因突变的信息是必不可少的。本文回顾了胃肠道间质瘤的临床病理特征,以及这些肿瘤的微创和多学科治疗选择。本文还讨论了这些肿瘤的诊断和治疗方法的未来前景。
{"title":"Current treatment strategies and future perspectives for gastrointestinal stromal tumors.","authors":"Yoichi Sugiyama,&nbsp;Masaru Sasaki,&nbsp;Mohei Kouyama,&nbsp;Tatsuya Tazaki,&nbsp;Shinya Takahashi,&nbsp;Atsushi Nakamitsu","doi":"10.4291/wjgp.v13.i1.15","DOIUrl":"https://doi.org/10.4291/wjgp.v13.i1.15","url":null,"abstract":"<p><p>Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that originate from the gastrointestinal tract, mostly from the stomach. GISTs are derived from the myenteric interstitial cells of Cajal and are caused by several mutations in the c-kit and platelet-derived growth factor receptor genes. Clinically, GISTs are detected by endoscopic and imaging findings and are diagnosed by immunostaining. Surgery is the first line of treatment, and if the tumor is relatively small, minimally invasive surgery such as laparoscopy is performed. In recent years, neoadjuvant therapy has been administered to patients with GISTs that are suspected of having a large size or infiltration to other organs. Postoperative adjuvant imatinib is the standard therapy for high-risk GISTs. It is important to assess the risk of recurrence after GIST resection. However, the effect of tyrosine kinase inhibitor use will vary by the mutation of c-kit genes and the site of mutation. Furthermore, information regarding gene mutation is indispensable when considering the treatment policy for recurrent GISTs. This article reviews the clinicopathological characteristics of GISTs along with the minimally invasive and multidisciplinary treatment options available for these tumors. The future perspectives for diagnostic and treatment approaches for these tumors have also been discussed.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"13 1","pages":"15-33"},"PeriodicalIF":0.0,"publicationDate":"2022-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/5e/WJGP-13-15.PMC8788163.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39588561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Combined antrum and corpus biopsy protocol improves Helicobacter pylori culture success. 联合上腔和体活检方案提高幽门螺杆菌培养的成功率。
Pub Date : 2022-01-22 DOI: 10.4291/wjgp.v13.i1.34
Denise E Brennan, Colm O'Morain, Deirdre McNamara, Sinead M Smith

Background: Helicobacter pylori (H. pylori) causes chronic gastritis, peptic ulcer disease, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Eradication rates have fallen, mainly due to antimicrobial resistance. Consensus guidelines recommend that first-line treatment is based on the local prevalence of antimicrobial resistance and that rescue therapies are guided by antimicrobial susceptibility testing (AST). However, H. pylori culture is challenging and culture-based AST is not routinely performed in the majority of hospitals. Optimisation of H. pylori culture from clinical specimens will enable more widespread AST to determine the most appropriate antimicrobials for H. pylori eradication.

Aim: To determine whether dual antrum and corpus biopsy sampling is superior to single antrum biopsy sampling for H. pylori culture.

Methods: The study received ethical approval from the joint research ethics committee of Tallaght University Hospital and St. James's Hospital. Patients referred for upper gastrointestinal endoscopy were invited to participate. Biopsies were collected in tubes containing Dent's transport medium and patient demographics were recorded. Biopsies were used to inoculate Colombia blood agar plates. Plates were incubated under microaerobic conditions and evaluated for the presence of H. pylori. Statistical analyses were performed using Graphpad PRISM. Continuous variables were compared using the two-tailed independent t-test. Categorical variables were compared using the two-tailed Fisher exact test. In all cases, a P value less than 0.05 was considered significant.

Results: In all, samples from 219 H. pylori-infected patients were analysed in the study. The mean age of recruited patients was 48 ± 14.9 years and 50.7% (n = 111) were male. The most common endoscopic finding was gastritis (58.9%; n = 129). Gastric ulcer was diagnosed in 4.6% (n = 10) of patients, while duodenal ulcer was diagnosed in 2.7% (n = 6). Single antrum biopsies were collected from 73 patients, whereas combined antrum and corpus biopsies were collected from 146 patients. There was no significant difference in age, sex or endoscopic findings between the two groups. H. pylori was successfully cultured in a significantly higher number of cases when combined antrum and corpus biopsies were used compared to a single antrum biopsy [64.4% (n = 94/146) vs 49.3% (36/73); P = 0.04)].

Conclusion: Combined corpus and antrum biopsy sampling improves H. pylori culture success compared to single antrum biopsy sampling.

背景:幽门螺杆菌引起慢性胃炎、消化性溃疡、胃腺癌和粘膜相关淋巴组织淋巴瘤。根除率已经下降,主要是由于抗菌素耐药性。共识指南建议根据当地抗菌素耐药性的流行情况进行一线治疗,并以抗菌素敏感性试验(AST)为指导进行抢救治疗。然而,幽门螺杆菌培养是具有挑战性的,基于培养的AST在大多数医院并不常规进行。从临床标本中优化幽门螺杆菌培养将使更广泛的AST确定最适合根除幽门螺杆菌的抗菌剂。目的:探讨双腔活检对幽门螺杆菌培养是否优于单腔活检。方法:本研究获得Tallaght大学医院和St. James医院联合研究伦理委员会的伦理批准。接受上消化道内窥镜检查的患者被邀请参加。在装有登特氏运输介质的管中收集活检,并记录患者人口统计数据。采用活组织检查接种哥伦比亚血琼脂平板。培养皿在微氧条件下孵育,并评估幽门螺杆菌的存在。使用Graphpad PRISM进行统计分析。连续变量的比较采用双尾独立t检验。分类变量比较采用双尾Fisher精确检验。在所有情况下,P值小于0.05被认为是显著的。结果:共分析了219例幽门螺旋杆菌感染患者的样本。入选患者的平均年龄为48±14.9岁,男性占50.7% (n = 111)。最常见的内镜检查结果是胃炎(58.9%;N = 129)。4.6% (n = 10)的患者被诊断为胃溃疡,2.7% (n = 6)的患者被诊断为十二指肠溃疡。73例患者接受了单独的胃窦活检,146例患者接受了联合胃窦和体活检。两组患者在年龄、性别或内窥镜检查结果上没有显著差异。与单独的胃窦活检相比,联合胃窦和体腔活检成功培养幽门螺杆菌的病例数量明显更高[64.4% (n = 94/146) vs 49.3% (36/73);P = 0.04)]。结论:与单独的胃窦活检取样相比,联合体腔活检取样可提高幽门螺杆菌培养成功率。
{"title":"Combined antrum and corpus biopsy protocol improves <i>Helicobacter pylori</i> culture success.","authors":"Denise E Brennan,&nbsp;Colm O'Morain,&nbsp;Deirdre McNamara,&nbsp;Sinead M Smith","doi":"10.4291/wjgp.v13.i1.34","DOIUrl":"https://doi.org/10.4291/wjgp.v13.i1.34","url":null,"abstract":"<p><strong>Background: </strong><i>Helicobacter pylori</i> (<i>H. pylori</i>) causes chronic gastritis, peptic ulcer disease, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Eradication rates have fallen, mainly due to antimicrobial resistance. Consensus guidelines recommend that first-line treatment is based on the local prevalence of antimicrobial resistance and that rescue therapies are guided by antimicrobial susceptibility testing (AST). However, <i>H. pylori</i> culture is challenging and culture-based AST is not routinely performed in the majority of hospitals. Optimisation of <i>H. pylori</i> culture from clinical specimens will enable more widespread AST to determine the most appropriate antimicrobials for <i>H. pylori</i> eradication.</p><p><strong>Aim: </strong>To determine whether dual antrum and corpus biopsy sampling is superior to single antrum biopsy sampling for <i>H. pylori</i> culture.</p><p><strong>Methods: </strong>The study received ethical approval from the joint research ethics committee of Tallaght University Hospital and St. James's Hospital. Patients referred for upper gastrointestinal endoscopy were invited to participate. Biopsies were collected in tubes containing Dent's transport medium and patient demographics were recorded. Biopsies were used to inoculate Colombia blood agar plates. Plates were incubated under microaerobic conditions and evaluated for the presence of <i>H. pylori.</i> Statistical analyses were performed using Graphpad PRISM. Continuous variables were compared using the two-tailed independent <i>t</i>-test. Categorical variables were compared using the two-tailed Fisher exact test. In all cases, a <i>P</i> value less than 0.05 was considered significant.</p><p><strong>Results: </strong>In all, samples from 219 <i>H. pylori</i>-infected patients were analysed in the study. The mean age of recruited patients was 48 ± 14.9 years and 50.7% (<i>n</i> = 111) were male. The most common endoscopic finding was gastritis (58.9%; <i>n</i> = 129). Gastric ulcer was diagnosed in 4.6% (<i>n</i> = 10) of patients, while duodenal ulcer was diagnosed in 2.7% (<i>n</i> = 6). Single antrum biopsies were collected from 73 patients, whereas combined antrum and corpus biopsies were collected from 146 patients. There was no significant difference in age, sex or endoscopic findings between the two groups. <i>H. pylori</i> was successfully cultured in a significantly higher number of cases when combined antrum and corpus biopsies were used compared to a single antrum biopsy [64.4% (<i>n</i> = 94/146) <i>vs</i> 49.3% (36/73); <i>P</i> = 0.04)].</p><p><strong>Conclusion: </strong>Combined corpus and antrum biopsy sampling improves <i>H. pylori</i> culture success compared to single antrum biopsy sampling.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"13 1","pages":"34-40"},"PeriodicalIF":0.0,"publicationDate":"2022-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/58/WJGP-13-34.PMC8788162.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39885981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Prediction of hereditary nonpolyposis colorectal cancer using mRNA MSH2 quantitative and the correlation with nonmodifiable factor. 利用 mRNA MSH2 定量预测遗传性非息肉病结直肠癌及其与非可改变因素的相关性。
Pub Date : 2021-11-22 DOI: 10.4291/wjgp.v12.i6.134
Tjahjadi Robert Tedjasaputra, Mochammad Hatta, Muh Nasrum Massi, Rosdiana Natzir, Agussalim Bukhari, Rina Masadah, Muh Lutfi Parewangi, Prihantono Prihantono, Rinda Nariswati, Vincent Tedjasaputra

Background: Hereditary non-polyposis colon cancer is a dominantly inherited syndrome of colorectal cancer (CRC), with heightened risk for younger population. Previous studies link its susceptibility to the DNA sequence polymorphism along with Amsterdam and Bethesda criteria. However, those fail in term of applicability.

Aim: To determine a clear cut-off of MSH2 gene expression for CRC heredity grouping factor. Further, the study also aims to examine the association of risk factors to the CRC heredity.

Methods: The cross-sectional study observed 71 respondents from May 2018 to December 2019 in determining the CRC hereditary status through MSH2 mRNA expression using reverse transcription-polymerase chain reaction and the disease's risk factors. Data were analyzed through Chi-Square, Fischer exact, t-test, Mann-Whitney, and multiple logistics.

Results: There are significant differences of MSH2 within CRC group among tissue and blood; yet, negative for significance between groups. Through the blood gene expression fifth percentile, the hereditary CRC cut-off is 11059 fc, dividing the 40 CRC respondents to 32.5% with hereditary CRC. Significant risk factors include age, family history, and staging. Nonetheless, after multivariate control, age is just a confounder. Further, the study develops a probability equation with area under the curve 82.2%.

Conclusion: Numerous factors have significant relations to heredity of CRC patients. However, true important factors are staging and family history, while age and others are confounders. The study also established a definite cut-off point for heredity CRC based on mRNA MSH2 expression, 11059 fc. These findings shall act as concrete foundations on further risk factors and/or genetical CRC future studies.

背景:遗传性非息肉病结肠癌是一种显性遗传的结直肠癌(CRC)综合征,年轻人患上该病的风险更高。以往的研究将其易感性与 DNA 序列多态性以及阿姆斯特丹和贝塞斯达标准联系起来。目的:为 CRC 遗传分组因素确定一个明确的 MSH2 基因表达临界值。此外,该研究还旨在探讨风险因素与 CRC 遗传的关联:该横断面研究于 2018 年 5 月至 2019 年 12 月期间对 71 名受访者进行了观察,通过使用反转录聚合酶链反应的 MSH2 mRNA 表达确定 CRC 遗传状态以及该疾病的风险因素。通过Chi-Square、Fischer exact、t检验、Mann-Whitney和多重物流对数据进行分析:结果:MSH2在CRC组内的组织和血液中差异有学意义;但在组间差异无学意义。通过血液基因表达第五百分位数,遗传性 CRC 的临界值为 11059 fc,将 40 名 CRC 受访者划分为 32.5%的遗传性 CRC。重要的风险因素包括年龄、家族史和分期。然而,经过多变量控制后,年龄只是一个混杂因素。此外,研究还得出了一个概率方程,曲线下面积为 82.2%:结论:许多因素与 CRC 患者的遗传有重要关系。然而,真正重要的因素是分期和家族史,而年龄和其他因素则是混杂因素。研究还根据 mRNA MSH2 的表达确定了遗传性 CRC 的临界点,即 11059 fc。这些发现将为今后进一步研究风险因素和/或遗传性 CRC 奠定坚实的基础。
{"title":"Prediction of hereditary nonpolyposis colorectal cancer using mRNA <i>MSH2</i> quantitative and the correlation with nonmodifiable factor.","authors":"Tjahjadi Robert Tedjasaputra, Mochammad Hatta, Muh Nasrum Massi, Rosdiana Natzir, Agussalim Bukhari, Rina Masadah, Muh Lutfi Parewangi, Prihantono Prihantono, Rinda Nariswati, Vincent Tedjasaputra","doi":"10.4291/wjgp.v12.i6.134","DOIUrl":"10.4291/wjgp.v12.i6.134","url":null,"abstract":"<p><strong>Background: </strong>Hereditary non-polyposis colon cancer is a dominantly inherited syndrome of colorectal cancer (CRC), with heightened risk for younger population. Previous studies link its susceptibility to the DNA sequence polymorphism along with Amsterdam and Bethesda criteria. However, those fail in term of applicability.</p><p><strong>Aim: </strong>To determine a clear cut-off of <i>MSH2</i> gene expression for CRC heredity grouping factor. Further, the study also aims to examine the association of risk factors to the CRC heredity.</p><p><strong>Methods: </strong>The cross-sectional study observed 71 respondents from May 2018 to December 2019 in determining the CRC hereditary status through <i>MSH2</i> mRNA expression using reverse transcription-polymerase chain reaction and the disease's risk factors. Data were analyzed through Chi-Square, Fischer exact, t-test, Mann-Whitney, and multiple logistics.</p><p><strong>Results: </strong>There are significant differences of <i>MSH2</i> within CRC group among tissue and blood; yet, negative for significance between groups. Through the blood gene expression fifth percentile, the hereditary CRC cut-off is 11059 fc, dividing the 40 CRC respondents to 32.5% with hereditary CRC. Significant risk factors include age, family history, and staging. Nonetheless, after multivariate control, age is just a confounder. Further, the study develops a probability equation with area under the curve 82.2%.</p><p><strong>Conclusion: </strong>Numerous factors have significant relations to heredity of CRC patients. However, true important factors are staging and family history, while age and others are confounders. The study also established a definite cut-off point for heredity CRC based on mRNA <i>MSH2</i> expression, 11059 fc. These findings shall act as concrete foundations on further risk factors and/or genetical CRC future studies.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"12 6","pages":"134-146"},"PeriodicalIF":0.0,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/57/WJGP-12-134.PMC8611184.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39790487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bacterial translocation in patients undergoing major gastrointestinal surgery and its role in postoperative sepsis. 胃肠大手术患者的细菌易位及其在术后脓毒症中的作用。
Pub Date : 2021-11-22 DOI: 10.4291/wjgp.v12.i6.106
Christos Doudakmanis, Konstantinos Bouliaris, Christina Kolla, Matthaios Efthimiou, Georgios D Koukoulis

Bacteria of the human intestinal microflora have a dual role. They promote digestion and are part of a defense mechanism against pathogens. These bacteria could become potential pathogens under certain circumstances. The term "bacterial translocation" describes the passage of bacteria of the gastrointestinal tract through the intestinal mucosa barrier to mesenteric lymph nodes and other organs. In some cases, the passage of bacteria and endotoxins could result in blood stream infections and in multiple organ failure. Open elective abdominal surgery more frequently results in malfunction of the intestinal barrier and subsequent bacterial translocation and blood stream infections than laparoscopic surgery. Postoperative sepsis is a common finding in patients who have undergone non-elective abdominal surgeries, including trauma patients treated with laparotomy. Postoperative sepsis is an emerging issue, as it changes the treatment plan in surgical patients and prolongs hospital stay. The association between bacterial translocation and postoperative sepsis could provide novel treatment options.

人类肠道菌群中的细菌具有双重作用。它们促进消化,是抵御病原体的防御机制的一部分。在某些情况下,这些细菌可能成为潜在的病原体。术语“细菌易位”描述了胃肠道细菌通过肠粘膜屏障进入肠系膜淋巴结和其他器官。在某些情况下,细菌和内毒素的通过可能导致血流感染和多器官衰竭。开放式择期腹部手术比腹腔镜手术更容易导致肠屏障功能障碍和随后的细菌移位和血流感染。术后脓毒症是接受非选择性腹部手术的患者的常见发现,包括开腹手术的创伤患者。术后脓毒症是一个新兴的问题,因为它改变了手术患者的治疗计划,延长了住院时间。细菌易位与术后脓毒症之间的关系可以提供新的治疗选择。
{"title":"Bacterial translocation in patients undergoing major gastrointestinal surgery and its role in postoperative sepsis.","authors":"Christos Doudakmanis,&nbsp;Konstantinos Bouliaris,&nbsp;Christina Kolla,&nbsp;Matthaios Efthimiou,&nbsp;Georgios D Koukoulis","doi":"10.4291/wjgp.v12.i6.106","DOIUrl":"https://doi.org/10.4291/wjgp.v12.i6.106","url":null,"abstract":"<p><p>Bacteria of the human intestinal microflora have a dual role. They promote digestion and are part of a defense mechanism against pathogens. These bacteria could become potential pathogens under certain circumstances. The term \"bacterial translocation\" describes the passage of bacteria of the gastrointestinal tract through the intestinal mucosa barrier to mesenteric lymph nodes and other organs. In some cases, the passage of bacteria and endotoxins could result in blood stream infections and in multiple organ failure. Open elective abdominal surgery more frequently results in malfunction of the intestinal barrier and subsequent bacterial translocation and blood stream infections than laparoscopic surgery. Postoperative sepsis is a common finding in patients who have undergone non-elective abdominal surgeries, including trauma patients treated with laparotomy. Postoperative sepsis is an emerging issue, as it changes the treatment plan in surgical patients and prolongs hospital stay. The association between bacterial translocation and postoperative sepsis could provide novel treatment options.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"12 6","pages":"106-114"},"PeriodicalIF":0.0,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/0f/WJGP-12-106.PMC8611185.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39701292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Chemokine receptor 8 expression may be linked to disease severity and elevated interleukin 6 secretion in acute pancreatitis. 趋化因子受体8的表达可能与急性胰腺炎的疾病严重程度和白细胞介素6分泌升高有关。
Pub Date : 2021-11-22 DOI: 10.4291/wjgp.v12.i6.115
Mwangala Nalisa, Ekene Emmanuel Nweke, Martin D Smith, Jones Omoshoro-Jones, John Ws Devar, Rebecca Metzger, Tanya N Augustine, Pascaline N Fru

Background: Acute pancreatitis (AP) is an inflammatory disease, which presents with epigastric pain and is clinically diagnosed by amylase and lipase three times the upper limit of normal. The 2012 Atlanta classification stratifies the severity of AP as one of three risk categories namely, mild AP (MAP), moderately severe AP (MSAP), and severe AP (SAP). Challenges in stratifying AP upon diagnosis suggest that a better understanding of the underlying complex pathophysiology may be beneficial.

Aim: To identify the role of the chemokine receptor 8 (CCR8), expressed by T-helper type-2 Lymphocytes and peritoneal macrophages, and its possible association to Interleukin (IL)-6 and AP stratification.

Methods: This study was a prospective case-control study. A total of 40 patients were recruited from the Chris Hani Baragwanath Academic Hospital and the Charlotte Maxeke Johannesburg Academic Hospital. Bioassays were performed on 29 patients (14 MAP, 11 MSAP, and 4 SAP) and 6 healthy controls as part of a preliminary study. A total of 12 mL of blood samples were collected at Day (D) 1, 3, 5, and 7 post epigastric pain. Using multiplex immunoassay panels, real-time polymerase chain reaction (qRT-PCR) arrays, and multicolour flow cytometry analysis, immune response-related proteins, genes, and cells were profiled respectively. GraphPad Prism™ software and fold change (FC) analysis was used to determine differences between the groups. P<0.05 was considered significant.

Results: The concentration of IL-6 was significantly different at D3 post epigastric pain in both the MAP group and MSAP group with P = 0.001 and P = 0.013 respectively, in a multiplex assay. When a FC of 2 was applied to identify differentially expressed genes using RT2 Profiler, CCR8 was shown to increase steadily with disease severity from MAP (1.33), MSAP (38.28) to SAP (1172.45) median FC. Further verification studies using RT-PCR showed fold change increases of CCR8 in MSAP and SAP ranging from 1000 to 1000000 times when represented as Log10, compared to healthy control respectively at D3. The findings also showed differing lymphocyte and monocyte cell frequency between the groups. With monocyte population frequency as high as 70% in MSAP at D3.

Conclusion: The higher levels of CCR8 and IL-6 in the severe patients and immune cell differences compared to MAP and controls provide an avenue for exploring AP stratification to improve management.

背景:急性胰腺炎(Acute pancreatitis, AP)是一种以胃脘痛为主要表现的炎症性疾病,临床诊断为淀粉酶和脂肪酶高于正常上限3倍。2012年亚特兰大分类将AP的严重程度分为三种风险类别之一,即轻度AP (MAP),中度AP (MSAP)和重度AP (SAP)。在诊断时对AP进行分层的挑战表明,更好地了解潜在的复杂病理生理可能是有益的。目的:探讨t -辅助性2型淋巴细胞和腹腔巨噬细胞表达的趋化因子受体8 (CCR8)在白细胞介素(IL)-6和AP分层中的作用及其可能的相关性。方法:本研究为前瞻性病例对照研究。从Chris Hani Baragwanath学术医院和Charlotte Maxeke约翰内斯堡学术医院共招募了40名患者。作为初步研究的一部分,对29名患者(14名MAP, 11名MSAP和4名SAP)和6名健康对照进行了生物测定。在胃脘痛后第1、3、5、7天共采集血样12 mL。利用多重免疫分析面板、实时聚合酶链反应(qRT-PCR)阵列和多色流式细胞术分析,分别对免疫反应相关蛋白、基因和细胞进行了分析。使用GraphPad Prism™软件和折叠变化(FC)分析来确定组间差异。结果:MAP组和MSAP组在胃脘痛后D3时IL-6浓度差异有统计学意义(P = 0.001和P = 0.013)。当使用RT2 Profiler应用2的FC来鉴定差异表达基因时,CCR8显示随着疾病严重程度的增加而稳步增加,从MAP (1.33), MSAP(38.28)到SAP(1172.45)中位FC。使用RT-PCR的进一步验证研究显示,与健康对照相比,在D3时,MSAP和SAP中的CCR8分别以Log10表示,增加了1000至1000000倍。研究结果还显示各组之间淋巴细胞和单核细胞的频率不同。D3时MSAP单核细胞群体频率高达70%。结论:重症患者CCR8和IL-6水平升高以及免疫细胞差异与MAP和对照组相比,为探索AP分层改善治疗提供了途径。
{"title":"Chemokine receptor 8 expression may be linked to disease severity and elevated interleukin 6 secretion in acute pancreatitis.","authors":"Mwangala Nalisa,&nbsp;Ekene Emmanuel Nweke,&nbsp;Martin D Smith,&nbsp;Jones Omoshoro-Jones,&nbsp;John Ws Devar,&nbsp;Rebecca Metzger,&nbsp;Tanya N Augustine,&nbsp;Pascaline N Fru","doi":"10.4291/wjgp.v12.i6.115","DOIUrl":"https://doi.org/10.4291/wjgp.v12.i6.115","url":null,"abstract":"<p><strong>Background: </strong>Acute pancreatitis (AP) is an inflammatory disease, which presents with epigastric pain and is clinically diagnosed by amylase and lipase three times the upper limit of normal. The 2012 Atlanta classification stratifies the severity of AP as one of three risk categories namely, mild AP (MAP), moderately severe AP (MSAP), and severe AP (SAP). Challenges in stratifying AP upon diagnosis suggest that a better understanding of the underlying complex pathophysiology may be beneficial.</p><p><strong>Aim: </strong>To identify the role of the chemokine receptor 8 (<i>CCR8</i>), expressed by T-helper type-2 Lymphocytes and peritoneal macrophages, and its possible association to Interleukin (IL)-6 and AP stratification.</p><p><strong>Methods: </strong>This study was a prospective case-control study. A total of 40 patients were recruited from the Chris Hani Baragwanath Academic Hospital and the Charlotte Maxeke Johannesburg Academic Hospital. Bioassays were performed on 29 patients (14 MAP, 11 MSAP, and 4 SAP) and 6 healthy controls as part of a preliminary study. A total of 12 mL of blood samples were collected at Day (D) 1, 3, 5, and 7 post epigastric pain. Using multiplex immunoassay panels, real-time polymerase chain reaction (qRT-PCR) arrays, and multicolour flow cytometry analysis, immune response-related proteins, genes, and cells were profiled respectively. GraphPad Prism™ software and fold change (FC) analysis was used to determine differences between the groups. <i>P</i><0.05 was considered significant.</p><p><strong>Results: </strong>The concentration of IL-6 was significantly different at D3 post epigastric pain in both the MAP group and MSAP group with <i>P</i> = 0.001 and <i>P</i> = 0.013 respectively, in a multiplex assay. When a FC of 2 was applied to identify differentially expressed genes using RT<sup>2</sup> Profiler, <i>CCR8</i> was shown to increase steadily with disease severity from MAP (1.33), MSAP (38.28) to SAP (1172.45) median FC. Further verification studies using RT-PCR showed fold change increases of <i>CCR8</i> in MSAP and SAP ranging from 1000 to 1000000 times when represented as Log<sub>10</sub>, compared to healthy control respectively at D3. The findings also showed differing lymphocyte and monocyte cell frequency between the groups. With monocyte population frequency as high as 70% in MSAP at D3.</p><p><strong>Conclusion: </strong>The higher levels of <i>CCR8</i> and IL-6 in the severe patients and immune cell differences compared to MAP and controls provide an avenue for exploring AP stratification to improve management.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"12 6","pages":"115-133"},"PeriodicalIF":0.0,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/35/WJGP-12-115.PMC8611186.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39701293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Cholangiocarcinoma and liver transplantation: What we know so far? 胆管癌和肝移植:到目前为止我们知道什么?
Pub Date : 2021-09-22 DOI: 10.4291/wjgp.v12.i5.84
Ali Reza Safarpour, Hassan Askari, Farshid Ejtehadi, Asaad Azarnezhad, Ehsan Raeis-Abdollahi, Amir Tajbakhsh, Mohammad Foad Abazari, Firoozeh Tarkesh, Alireza Shamsaeefar, Ramin Niknam, Gholam Reza Sivandzadeh, Kamran Bagheri Lankarani, Fardad Ejtehadi

Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.

胆管癌(CCA)是一种在世界范围内发病率越来越高的癌症,起源于胆管上皮细胞胆管细胞。肿瘤开始时不明显,特点是高级别肿瘤,预后差,复发风险高。肝移植已被广泛接受为CCA的治疗选择。肝移植有望在不可切除的肝门CCA和肝内CCA的姑息治疗和治愈治疗中发挥关键作用。本研究的目的是确定哪些CCA患者应该接受肝移植而不是切除,尽管报道的移植后复发率平均约为20%。本文综述了CCA的分子研究前沿和CCA肝移植的发展方向。
{"title":"Cholangiocarcinoma and liver transplantation: What we know so far?","authors":"Ali Reza Safarpour,&nbsp;Hassan Askari,&nbsp;Farshid Ejtehadi,&nbsp;Asaad Azarnezhad,&nbsp;Ehsan Raeis-Abdollahi,&nbsp;Amir Tajbakhsh,&nbsp;Mohammad Foad Abazari,&nbsp;Firoozeh Tarkesh,&nbsp;Alireza Shamsaeefar,&nbsp;Ramin Niknam,&nbsp;Gholam Reza Sivandzadeh,&nbsp;Kamran Bagheri Lankarani,&nbsp;Fardad Ejtehadi","doi":"10.4291/wjgp.v12.i5.84","DOIUrl":"https://doi.org/10.4291/wjgp.v12.i5.84","url":null,"abstract":"<p><p>Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"12 5","pages":"84-105"},"PeriodicalIF":0.0,"publicationDate":"2021-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/9c/WJGP-12-84.PMC8481789.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39564783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
World Journal of Gastrointestinal Pathophysiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1